Is serine racemase (SRR) a second hit target for LRRK2-G2019S induced Parkinson's disease?
Sarah Louise Nickels1
Jens Christian Schwamborn2
1.Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Belvaux, Luxembourg;Riken Institute for Medical Sciences (IMS), Kanagawa, Japan2.Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Belvaux, Luxembourg
摘要：To date, at least 7 million people are suffering from Parkinson's disease (PD) worldwide, which is the second most prevalent, age-associated, and progressive neurodegenerative disorder (Tysnes and Storstein, 2017). Given the accelerated global pace of aging, it becomes of fundamental importance that we start understanding the origins of neurodegeneration in order to develop effective disease modifying treatments. Most PD patients suffer from a combination of motor and non-motor disabilities. The motor symptoms typically manifest in bradykinesia, tremor and rigidity (Hoehn and Yahr, 2001). The physical decline is directly linked to the loss of dopaminergic neurons in the substantia nigra pars compacta of the midbrain, which disrupts dopamine signalling responsible for movement and mobility (Lanciego et al., 2012).
机标关键词：
论文发表日期：2021-03-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：2( 498-499 )